Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed. This open-label, phase 3 trial evalua...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
23.09.2025
|
| Schlagworte: | |
| ISSN: | 1537-6591, 1537-6591 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed.
This open-label, phase 3 trial evaluated revaccination with 50-µg mRNA-1345 administered 12 months after primary vaccination in participants aged ≥50 years. The primary objectives were the immunogenicity (RSV-A and RSV-B neutralizing antibody [nAb] responses), tolerability, and safety of revaccination.
543 participants were revaccinated. Most adverse reactions were mild/moderate (median duration, 2 days), with no new safety concerns identified. Co-primary immunogenicity endpoints met pre-specified non-inferiority criteria based on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination). At Day 29, nAb GMRs (95% CI) were 1.08 (1.0-1.17) for RSV-A and 0.91 (0.84-0.98) for RSV-B. Seroresponse rates (≥4-fold rise from baseline; 95% CI) at Day 29 were 77.5% (73.7-81.0) for RSV-A and 47.5% (43.2-51.9) for RSV-B, with a ≥2-fold rise in titers observed in 91.6% (88.9-93.8) and 69.8% (65.7-73.8) of participants, respectively. Following primary vaccination, RSV nAb titers increased by Day 29 and gradually declined over 12 months, yet remained above baseline levels. Revaccination at 12 months increased nAb titers, similar to the response observed after the primary dose.
Revaccination of adults ≥50 years with mRNA-1345 was well-tolerated with a safety profile consistent with the primary dose. RSV nAb at Day 29 were non-inferior to those after a primary mRNA-1345 dose, with antibody response persisting for 12 months.
ClinicalTrials.gov: NCT05330975. |
|---|---|
| AbstractList | mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed.BACKGROUNDmRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed.This open-label, phase 3 trial evaluated revaccination with 50-µg mRNA-1345 administered 12 months after primary vaccination in participants aged ≥50 years. The primary objectives were the immunogenicity (RSV-A and RSV-B neutralizing antibody [nAb] responses), tolerability, and safety of revaccination.METHODSThis open-label, phase 3 trial evaluated revaccination with 50-µg mRNA-1345 administered 12 months after primary vaccination in participants aged ≥50 years. The primary objectives were the immunogenicity (RSV-A and RSV-B neutralizing antibody [nAb] responses), tolerability, and safety of revaccination.543 participants were revaccinated. Most adverse reactions were mild/moderate (median duration, 2 days), with no new safety concerns identified. Co-primary immunogenicity endpoints met pre-specified non-inferiority criteria based on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination). At Day 29, nAb GMRs (95% CI) were 1.08 (1.0-1.17) for RSV-A and 0.91 (0.84-0.98) for RSV-B. Seroresponse rates (≥4-fold rise from baseline; 95% CI) at Day 29 were 77.5% (73.7-81.0) for RSV-A and 47.5% (43.2-51.9) for RSV-B, with a ≥2-fold rise in titers observed in 91.6% (88.9-93.8) and 69.8% (65.7-73.8) of participants, respectively. Following primary vaccination, RSV nAb titers increased by Day 29 and gradually declined over 12 months, yet remained above baseline levels. Revaccination at 12 months increased nAb titers, similar to the response observed after the primary dose.RESULTS543 participants were revaccinated. Most adverse reactions were mild/moderate (median duration, 2 days), with no new safety concerns identified. Co-primary immunogenicity endpoints met pre-specified non-inferiority criteria based on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination). At Day 29, nAb GMRs (95% CI) were 1.08 (1.0-1.17) for RSV-A and 0.91 (0.84-0.98) for RSV-B. Seroresponse rates (≥4-fold rise from baseline; 95% CI) at Day 29 were 77.5% (73.7-81.0) for RSV-A and 47.5% (43.2-51.9) for RSV-B, with a ≥2-fold rise in titers observed in 91.6% (88.9-93.8) and 69.8% (65.7-73.8) of participants, respectively. Following primary vaccination, RSV nAb titers increased by Day 29 and gradually declined over 12 months, yet remained above baseline levels. Revaccination at 12 months increased nAb titers, similar to the response observed after the primary dose.Revaccination of adults ≥50 years with mRNA-1345 was well-tolerated with a safety profile consistent with the primary dose. RSV nAb at Day 29 were non-inferior to those after a primary mRNA-1345 dose, with antibody response persisting for 12 months.CONCLUSIONSRevaccination of adults ≥50 years with mRNA-1345 was well-tolerated with a safety profile consistent with the primary dose. RSV nAb at Day 29 were non-inferior to those after a primary mRNA-1345 dose, with antibody response persisting for 12 months.ClinicalTrials.gov: NCT05330975.CLINICAL TRIALS REGISTRATIONClinicalTrials.gov: NCT05330975. mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years. Durability of efficacy is being evaluated in clinical trials. Data on revaccination in adults are needed. This open-label, phase 3 trial evaluated revaccination with 50-µg mRNA-1345 administered 12 months after primary vaccination in participants aged ≥50 years. The primary objectives were the immunogenicity (RSV-A and RSV-B neutralizing antibody [nAb] responses), tolerability, and safety of revaccination. 543 participants were revaccinated. Most adverse reactions were mild/moderate (median duration, 2 days), with no new safety concerns identified. Co-primary immunogenicity endpoints met pre-specified non-inferiority criteria based on Day 29 geometric mean titer ratios (GMRs; revaccination vs primary vaccination). At Day 29, nAb GMRs (95% CI) were 1.08 (1.0-1.17) for RSV-A and 0.91 (0.84-0.98) for RSV-B. Seroresponse rates (≥4-fold rise from baseline; 95% CI) at Day 29 were 77.5% (73.7-81.0) for RSV-A and 47.5% (43.2-51.9) for RSV-B, with a ≥2-fold rise in titers observed in 91.6% (88.9-93.8) and 69.8% (65.7-73.8) of participants, respectively. Following primary vaccination, RSV nAb titers increased by Day 29 and gradually declined over 12 months, yet remained above baseline levels. Revaccination at 12 months increased nAb titers, similar to the response observed after the primary dose. Revaccination of adults ≥50 years with mRNA-1345 was well-tolerated with a safety profile consistent with the primary dose. RSV nAb at Day 29 were non-inferior to those after a primary mRNA-1345 dose, with antibody response persisting for 12 months. ClinicalTrials.gov: NCT05330975. |
| Author | Kapoor, Archana Das, Rituparna Reuter, Caroline Wilson, Lauren Du, Jiejun Wang, Xiaowei Lan, Lan Righi, Vinicius Stoszek, Sonia K Cardona, Jose F Zhou, Honghong Shaw, Christine A Dhar, Rakesh Goswami, Jaya Wilson, Eleanor Simorellis, Alana K Collins, Avi Caso, Jorge Hsu, Denise C |
| Author_xml | – sequence: 1 givenname: Jaya surname: Goswami fullname: Goswami, Jaya organization: Moderna, Inc., Cambridge, MA, USA – sequence: 2 givenname: Jose F orcidid: 0009-0009-1601-1461 surname: Cardona fullname: Cardona, Jose F organization: Indago Research and Health Centre, Hialeah, Florida, USA – sequence: 3 givenname: Jorge surname: Caso fullname: Caso, Jorge organization: Suncoast Research Associates LLC, Miami, Florida, USA – sequence: 4 givenname: Denise C surname: Hsu fullname: Hsu, Denise C organization: Moderna, Inc., Cambridge, MA, USA – sequence: 5 givenname: Alana K surname: Simorellis fullname: Simorellis, Alana K organization: Moderna, Inc., Cambridge, MA, USA – sequence: 6 givenname: Lauren surname: Wilson fullname: Wilson, Lauren organization: Moderna, Inc., Cambridge, MA, USA – sequence: 7 givenname: Rakesh surname: Dhar fullname: Dhar, Rakesh organization: Moderna, Inc., Cambridge, MA, USA – sequence: 8 givenname: Xiaowei surname: Wang fullname: Wang, Xiaowei organization: Moderna, Inc., Cambridge, MA, USA – sequence: 9 givenname: Archana surname: Kapoor fullname: Kapoor, Archana organization: Moderna, Inc., Cambridge, MA, USA – sequence: 10 givenname: Avi surname: Collins fullname: Collins, Avi organization: Moderna, Inc., Cambridge, MA, USA – sequence: 11 givenname: Vinicius surname: Righi fullname: Righi, Vinicius organization: Moderna, Inc., Cambridge, MA, USA – sequence: 12 givenname: Lan surname: Lan fullname: Lan, Lan organization: Moderna, Inc., Cambridge, MA, USA – sequence: 13 givenname: Jiejun surname: Du fullname: Du, Jiejun organization: Moderna, Inc., Cambridge, MA, USA – sequence: 14 givenname: Honghong surname: Zhou fullname: Zhou, Honghong organization: Moderna, Inc., Cambridge, MA, USA – sequence: 15 givenname: Sonia K surname: Stoszek fullname: Stoszek, Sonia K organization: Moderna, Inc., Cambridge, MA, USA – sequence: 16 givenname: Christine A surname: Shaw fullname: Shaw, Christine A organization: Moderna, Inc., Cambridge, MA, USA – sequence: 17 givenname: Caroline surname: Reuter fullname: Reuter, Caroline organization: Moderna, Inc., Cambridge, MA, USA – sequence: 18 givenname: Eleanor orcidid: 0000-0002-4855-514X surname: Wilson fullname: Wilson, Eleanor organization: Moderna, Inc., Cambridge, MA, USA – sequence: 19 givenname: Rituparna surname: Das fullname: Das, Rituparna organization: Moderna, Inc., Cambridge, MA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40988124$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkElO5EAQRVMtEPOKPYplLzDkWGUvSzTQSEwqBqlXpbAzXGTLzqx2pkEcgYP0AbgSJ8FMEotQxA-9_6WIdbbkgyfGtgXfE7xQ-5WzQ2FthPnB1oRR42xkCrH0bV5l6zH-5VyInJsVtqp5kedC6jX2fIU1pcdduA4NdVi6xr0p9BZO2rb3YU7eVcMOQg1Tuseqch6TCx4eXLqDdno-yYTS5s3zruD2nSGYzNH5mGB6dbsLE9s672KijiwICWfBp7sIR6FpwoPzc0C47FyL3SP8CpHA-cHSNykOMYPj5em_4fCHsIubbLnGJtLWZ99gN0eH1we_s9OL45ODyWlWSaFTVmirRlJaVXI1GpdcjyRqKhTlWCLysRZS5cKQFqQIC8lVbXJhB0wYW9tKbrCfH7mLLvzrKaZZ62JFTYOeQh9nShqVD7_NzYDufKJ92ZKdLT4umX29Wb4CFqqAnA |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| Copyright_xml | – notice: The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| DBID | NPM 7X8 |
| DOI | 10.1093/cid/ciaf515 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| ExternalDocumentID | 40988124 |
| Genre | Journal Article |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 29B 36B 4.4 48X 5GY 5RE 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGKEF AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DILTD DU5 D~K E3Z EBS EE~ ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JLS JSG JXSIZ KAQDR KOP KSI KSN L7B MHKGH MJL N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TMA TR2 X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8 |
| ID | FETCH-LOGICAL-c214t-94d3622d3b0367b0462a4e93e8abaa074123815e41e3ea9203f581d46215dfdc2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001593493100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Thu Sep 25 00:25:04 EDT 2025 Thu Sep 25 01:50:59 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | mRNA RSV vaccine revaccination respiratory syncytial virus safety immunogenicity |
| Language | English |
| License | The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c214t-94d3622d3b0367b0462a4e93e8abaa074123815e41e3ea9203f581d46215dfdc2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0009-0009-1601-1461 0000-0002-4855-514X |
| OpenAccessLink | https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaf515/64356743/ciaf515.pdf |
| PMID | 40988124 |
| PQID | 3253859185 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3253859185 pubmed_primary_40988124 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Sep-23 |
| PublicationDateYYYYMMDD | 2025-09-23 |
| PublicationDate_xml | – month: 09 year: 2025 text: 2025-Sep-23 day: 23 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical infectious diseases |
| PublicationTitleAlternate | Clin Infect Dis |
| PublicationYear | 2025 |
| SSID | ssj0011805 |
| Score | 2.4901369 |
| SecondaryResourceType | online_first |
| Snippet | mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals ≥60 years.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| Title | Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40988124 https://www.proquest.com/docview/3253859185 |
| WOSCitedRecordID | wos001593493100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELYKRagXKD-FQosGiWOtNo5NNie0Alb00NVqW6rltHLscbtSSdomLeoj8CA8AK_Ek_RzklVPSEhcIlnyWLHm77PHMyPEO0AM9pnzMuhcS-0KJwuXacla2xCsUl6FttlENh4PZrN80l-41f2zyqVNbA21r1y8I99NFVTT5HAvH84vZOwaFaOrfQuNe2I1BZSJUp3N7qIIyaB9wgilzuR70Pb5eTjE7zqwGpsPJjF_x5atjxk9_t-_WxePenRJw04cnogVLp-Khwd9_PyZ-H1oAzc3O3RUnfFlV6IbI1t62o-JIhXECVObG6oCTfnaOtC1vKN4YUvfp-OhTFJtIk07ouN2DtPwxC4ANWl6eLxDy5K8sREoJYpgOZrTmkYQuuoHnCVZmnRlLuhTVTMtSpBcnTU1lgHFn5-_zB59gxLWz8XX0eejj19k37RBOpXoRubawycqnxbwjVkRc1-t5jzlgS2sjQAmggTDOuGUba720mCAmTEtMT54pzbE_bIq-aUg7wGuvI3FS3EMzIDkgJ6wiDOQIXZhU7xdMmMOpYiRDltydVXP79ixKV50HJ2fd9ua40A7iKjm1T9QvxZrKvb7jVGodEusBpgE3hYP3HWzqC_ftNKG73hycAtfH-Cl |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+Tolerability%2C+and+Immunogenicity+of+Revaccination+with+mRNA-1345%2C+an+mRNA+Vaccine+Against+RSV%2C+Administered+12+Months+Following+a+Primary+Dose+in+Adults+Aged+%E2%89%A550+Years&rft.jtitle=Clinical+infectious+diseases&rft.au=Goswami%2C+Jaya&rft.au=Cardona%2C+Jose+F&rft.au=Caso%2C+Jorge&rft.au=Hsu%2C+Denise+C&rft.date=2025-09-23&rft.issn=1537-6591&rft.eissn=1537-6591&rft_id=info:doi/10.1093%2Fcid%2Fciaf515&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |